Research Funding

  • December 14, 2022 - December 13, 2024 - Enhancing the precision of targeted therapies for EGFR-mutant lung cancer , Principal Investigator . Sponsor: Lung Cancer Research Foundation, Sponsor Award ID:

Education

06/2022 - Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
06/2018 - Internal Medicine, Brigham and Women's Hospital, Harvard Medical School
MD, 06/2016 - , University of California, San Francisco
PhD, 09/2013 - Chemical Biology, University of California, San Francisco

Honors & Awards

  • Forbes 30 Under 30: Science & Healthcare, Forbes Magazine, 2014
  • Joseph E. Mayer Award, University of California, San Diego, 2007
  • Phi Beta Kappa, University of California, San Diego, 2007
  • Thomas E. Curtis Scholarship, University of California, San Diego, 2006

Selected Publications

  1. Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, Haura EB, Villaruz LC. Overcoming KRAS-Mutant Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-11.  View on PubMed
  2. Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016 11; 15(11):771-785.  View on PubMed
  3. Schroeder CM, Ostrem JM, Hertz NT, Vale RD. A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region. Elife. 2014 Oct 01; 3:e03351.  View on PubMed
  4. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, Chien HC, Zhang Y, Morrissey KM, Liu J, Ostrem J, Younger NS, Kurhanewicz J, Shokat KM, Ashrafi K, Giacomini KM. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A. 2014 Jul 08; 111(27):9983-8.  View on PubMed
  5. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 28; 503(7477):548-51.  View on PubMed

Go to UCSF Profiles, powered by CTSI